331 – 340 of 458
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2001
-
Mark
Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml
(
- Contribution to journal › Article
-
Mark
Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146
(
- Contribution to journal › Article
-
Mark
Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level
(
- Contribution to journal › Article
-
Mark
Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues
(
- Contribution to journal › Article
-
Mark
Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing
(
- Contribution to journal › Article
-
Mark
Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing
(
- Contribution to journal › Article
-
Mark
A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: use of a catcher antibody specific for the complexed/cleaved form of the inhibitor
(
- Contribution to journal › Article
-
Mark
Dual-label detection of amplified products in quantitative RT-PCR assay using lanthanide-labeled probes
(
- Contribution to journal › Article
-
Mark
The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease
(
- Contribution to journal › Article
-
Mark
Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers
(
- Contribution to journal › Article